Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2020-04-28 Remuneration Information
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
Vistin Pharma ASA : Call for annual general meeting
Remuneration Information Classification · 98% confidence The document explicitly states its purpose: "Statement regarding the determination of salary and other remuneration to Executive Management" and details the company's salary policy, the function of the remuneration committee, and specific details on fixed salary, bonuses, pension plans, and share-based incentives for senior management. This content directly aligns with the definition of a Remuneration Information document, which corresponds to the DEF 14A filing type in the US context, or similar governance filings related to executive pay disclosure. Given the provided options, 'DEF 14A' (Proxy Solicitation & Information Statement, often used for remuneration reports in this context, although 'Remuneration Information' is the specific description provided for DEF 14A) is the most appropriate fit, as it deals with compensation disclosure for management.
2020-04-28 English
Vistin Pharma ASA : Call for annual general meeting
AGM Information Classification · 99% confidence The document text explicitly contains the phrases "INNKALLING TIL ORDINÆR GENERAL FORSAMLING" (Calling Notice for Annual General Meeting) and "CALLING NOTICE FOR ANNUAL GENERAL MEETING". It details the agenda and logistics for a meeting scheduled for May 19, 2020. This content directly corresponds to the materials prepared for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2020-04-28 Norwegian
Vistin Pharma ASA : Call for annual general meeting
AGM Information Classification · 98% confidence The document explicitly states 'Vistin Pharma ASA : Call for annual general meeting' in the title and body. It announces the date and format (digital) of the Annual General Meeting (AGM) and mentions that related documents will be made available. Since this is an announcement/call for the meeting itself, and not the detailed voting results (DVA) or the full set of proxy materials (PSI), the most appropriate classification is AGM Information (AGM-R). The document length is short (1196 chars), but the content is specifically about the meeting notice, not just announcing that a report is attached, making AGM-R more precise than RPA or RNS.
2020-04-28 English
Vistin Pharma ASA: Annual Report for 2019
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2019' and contains comprehensive sections including the Directors' Report, Operating Performance, Financial Results, Liquidity and Financial Position, Events after the Balance Sheet Date, and Corporate Social Responsibility. It provides detailed financial data and management analysis for the full fiscal year 2019, fitting the definition of an Annual Report (10-K). FY 2019
2020-04-23 English
Vistin Pharma ASA: Annual Report for 2019
Report Publication Announcement Classification · 98% confidence The document is very short (585 characters) and explicitly states: 'Please find attached the Annual Report for 2019 for Vistin Pharma ASA.' It announces the availability of the Annual Report but is not the report itself. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating a report is attached or published should be classified as a Report Publication Announcement (RPA). Although the title mentions 'Annual Report', the content structure strongly suggests an announcement about the report's release, not the full 10-K document.
2020-04-23 English
Vistin Pharma ASA: Expansion of the metformin manufacturing capacity
Report Publication Announcement Classification · 99% confidence The document is a short announcement dated April 23, 2020, from Vistin Pharma ASA. It explicitly states that the Board of Directors approved an investment to double the metformin production capacity. This action relates directly to the company's financing, capital structure, or fundraising activities, as it involves a NOK 100 million investment financed through cash and cash flow. This aligns best with the 'Capital/Financing Update' category, which covers company fundraising and capital structure changes.
2020-04-23 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.